Your cart is empty.
In vitro diagnostics (IVD) is central to the provision of healthcare globally, and is estimated to be worth in excess of $8.2 billion (€7.3 billion) a year in China alone.1 Despite this, the Chinese IVD landscape has historically been controlled by large international providers, with few domestic instrumentation and assay suppliers. Start-up company Shenzen AiTe is looking to change this, with the development of diagnostic platforms and assays offering rapid detection for a wide range of blood-based markers.
NGNY Devices is striving to fully automate laborious pre-analytical sample processing for clinical testing, helping to increase throughput and reduce human error. Its systems are already providing advanced sample sorting and aliquoting across Europe, offering a significant advantage over manual sample handling for busy clinical labs.
Next generation sequencing is now in widespread use throughout the life sciences sector, but the commonly used short-read sequencing methods are often subject to GC base pair bias. Combined with the inherent mapping ambiguity of the short reads, this often results in fragmented genome assemblies, creating a demand for technologies offering longer reads that simplify analysis and yield more complete sequences. Using its proprietary technology, Pacific Biosciences is able to offer longer reads, more uniform coverage and high accuracy, supporting advanced genomics, full-length transcript sequencing and epigenetics.